230 related articles for article (PubMed ID: 9787178)
21. Expression of growth factors and growth factor receptors in capillary hemangioblastoma.
Böhling T; Hatva E; Kujala M; Claesson-Welsh L; Alitalo K; Haltia M
J Neuropathol Exp Neurol; 1996 May; 55(5):522-7. PubMed ID: 8627342
[TBL] [Abstract][Full Text] [Related]
22. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
[TBL] [Abstract][Full Text] [Related]
23. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
24. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.
Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S
Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597
[TBL] [Abstract][Full Text] [Related]
25. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene.
Gnarra JR; Zhou S; Merrill MJ; Wagner JR; Krumm A; Papavassiliou E; Oldfield EH; Klausner RD; Linehan WM
Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10589-94. PubMed ID: 8855222
[TBL] [Abstract][Full Text] [Related]
26. Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity.
Blankenship C; Naglich JG; Whaley JM; Seizinger B; Kley N
Oncogene; 1999 Feb; 18(8):1529-35. PubMed ID: 10102622
[TBL] [Abstract][Full Text] [Related]
27. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
Iliopoulos O; Levy AP; Jiang C; Kaelin WG; Goldberg MA
Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10595-9. PubMed ID: 8855223
[TBL] [Abstract][Full Text] [Related]
28. Molecular pathology of eyes with von Hippel-Lindau (VHL) Disease: a review.
Chan CC; Collins AB; Chew EY
Retina; 2007 Jan; 27(1):1-7. PubMed ID: 17218907
[TBL] [Abstract][Full Text] [Related]
29. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
Jensen RL; Gillespie D; House P; Layfield L; Shelton C
J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285
[TBL] [Abstract][Full Text] [Related]
30. Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas.
Lee JY; Dong SM; Park WS; Yoo NJ; Kim CS; Jang JJ; Chi JG; Zbar B; Lubensky IA; Linehan WM; Vortmeyer AO; Zhuang Z
Cancer Res; 1998 Feb; 58(3):504-8. PubMed ID: 9458097
[TBL] [Abstract][Full Text] [Related]
31. Expression of vascular endothelial growth factor-b in human astrocytoma.
Gollmer JC; Ladoux A; Gioanni J; Paquis P; Dubreuil A; Chatel M; Frelin C
Neuro Oncol; 2000 Apr; 2(2):80-6. PubMed ID: 11303624
[TBL] [Abstract][Full Text] [Related]
32. Expression of vascular endothelial growth factor in von Hippel-Lindau syndrome-associated papillary cystadenoma of the epididymis.
Leung SY; Chan AS; Wong MP; Yuen ST; Fan YW; Chung LP
Hum Pathol; 1998 Nov; 29(11):1322-4. PubMed ID: 9824115
[TBL] [Abstract][Full Text] [Related]
33. The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways.
Pal S; Claffey KP; Dvorak HF; Mukhopadhyay D
J Biol Chem; 1997 Oct; 272(44):27509-12. PubMed ID: 9346879
[TBL] [Abstract][Full Text] [Related]
34. Developmental effects of von Hippel-Lindau gene deficiency.
Vortmeyer AO; Yuan Q; Lee YS; Zhuang Z; Oldfield EH
Ann Neurol; 2004 May; 55(5):721-8. PubMed ID: 15122713
[TBL] [Abstract][Full Text] [Related]
35. Intronic mutation of the VHL gene associated with central nervous system hemangioblastomas in two Chinese families with Von Hippel-Lindau disease: case report.
Liu Z; Zhou J; Li L; Yi Z; Lu R; Li C; Gong K
BMC Med Genet; 2020 Oct; 21(1):191. PubMed ID: 33004005
[TBL] [Abstract][Full Text] [Related]
36. Hypoxia mediated expression of stem cell markers in VHL-associated hemangioblastomas.
Ponnaluri VK; Vavilala DT; Prakash S; Mukherji M
Biochem Biophys Res Commun; 2013 Aug; 438(1):71-7. PubMed ID: 23872148
[TBL] [Abstract][Full Text] [Related]
37. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma.
Igarashi H; Esumi M; Ishida H; Okada K
Cancer; 2002 Jul; 95(1):47-53. PubMed ID: 12115316
[TBL] [Abstract][Full Text] [Related]
38. Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma.
Olschwang S; Richard S; Boisson C; Giraud S; Laurent-Puig P; Resche F; Thomas G
Hum Mutat; 1998; 12(6):424-30. PubMed ID: 9829912
[TBL] [Abstract][Full Text] [Related]
39. Endogenous von Hippel-Lindau tumor suppressor protein regulates catecholaminergic phenotype in PC12 cells.
Bauer AL; Paulding WR; Striet JB; Schnell PO; Czyzyk-Krzeska MF
Cancer Res; 2002 Mar; 62(6):1682-7. PubMed ID: 11912140
[TBL] [Abstract][Full Text] [Related]
40. The molecular basis of von Hippel-Lindau disease.
Iliopoulos O; Kaelin WG
Mol Med; 1997 May; 3(5):289-93. PubMed ID: 9205944
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
